Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib.
Öcal O, Schinner R, Schütte K, de Toni EN, Loewe C, van Delden O, Vandecaveye V, Gebauer B, Zech CJ, Sengel C, Bargellini I, Gasbarrini A, Sangro B, Pech M, Malfertheiner P, Ricke J, Seidensticker M; SORAMIC study group.
Öcal O, et al. Among authors: schinner r.
Cancer Imaging. 2022 Jan 4;22(1):1. doi: 10.1186/s40644-021-00439-x.
Cancer Imaging. 2022.
PMID: 34983668
Free PMC article.